✦ LIBER ✦

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

✍ Scribed by Tabernero, Josep; Van Cutsem, Eric; Lakomý, Radek; Prausová, Jana; Ruff, Paul; van Hazel, Guy A.; Moiseyenko, Vladimir M.; Ferry, David R.; McKendrick, Joseph J.; Soussan-Lazard, Karen; Chevalier, Soazig; Allegra, Carmen J.

Book ID: 122197599
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 706 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.09.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results From VELOUR, a Phase 3 Study of

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

✍ J. Tabernero; E. Van Cutsem; R. Lakomy; J. Prausova; P. Ruff; G. Van Hazel; V Mo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Addition of Aflibercept to Fluorouracil,

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

✍ Van Cutsem, E.; Tabernero, J.; Lakomy, R.; Prenen, H.; Prausova, J.; Macarulla, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 532 KB

Efficacy and safety of bevacizumab-based

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

✍ Ducreux, M.; Adenis, A.; Pignon, J.-P.; François, E.; Chauffert, B.; Ichanté, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 602 KB

Aflibercept versus placebo in combinatio

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

✍ Tannock, Ian F; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla Thellenberg; Fl 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 310 KB